Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

Company on Target to File Supplemental New Drug Application in the Fourth

Quarter

FRAZER, Pa., Aug. 16 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced positive results from a 12-week, Phase 3 clinical trial of FENTORA(R) (fentanyl buccal tablet) [C-II] in patients with breakthrough pain associated with a broad range of chronic non-cancer pain conditions. The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough pain who were already receiving and who were tolerant to opioid therapy for their underlying persistent pain. FENTORA is approved only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

"We are excited to complete our Phase 3 program with this third and final controlled study. These data show similar positive outcomes as those with FENTORA in treating breakthrough pain in opioid-tolerant patients with cancer, chronic neuropathic pain, and chronic low-back pain," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "We plan to submit these data to the Food and Drug Administration in the fourth quarter as part of our supplemental New Drug Application."

About the Study

The double-blind, placebo-controlled, variable dose Phase 3 trial included 148 patients. The primary endpoint was the Sum of Pain Intensity Differences from five to 60 minutes (SPID(60)) as assessed after 12 weeks of treatment. SPID(60) is a measure that assesses analgesic efficacy of a pain medication over the first 60 minutes after treatment. Patients treated with FENTORA showed a statistically significant improvement on the primary endpoint (p<0.0001) compared with placebo. FENTORA was general
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... Brady ... new video: 3 Ways to GHS Labels . This video provides useful ... Harmonized System (GHS) by effectively labeling chemical containers. , “With the fourth and ...
(Date:7/27/2015)... -- According to the new Market Research Report ... by Application (Biobanking, Regenerative Medicine, Drug Discovery), by Geography ( ... Asia-Pacific , Rest of the World) - ... was valued at $247.7 million in 2014, which is estimated ... CAGR of 18.2% between 2014 and 2019. Browse ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... Visual Assay ... and celebrate the top 100 most innovative technologies and services of the past year. ... named in the Software/Services category. The winners will be announced at the 2015 R&D ...
(Date:7/24/2015)... (PRWEB) , ... July 24, 2015 , ... VetStem Biopharma, ... Center in support of stem cell therapy training and clinical opportunities. , “We are ... opportunity to veterinarians in the San Diego area. Stem cell therapy is an established ...
Breaking Biology Technology:Brady Releases “3 Roads to GHS Labels” Video 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Visual Assay® Named Finalist in 53rd Annual R&D 100 Awards 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 2VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center. 3
... 2012  Paratek Pharmaceuticals, Inc. today announced that ... has been appointed President, Chief Executive Officer and ... his resignation earlier this year.  In addition, Evan ... and Wyeth and who led regulatory approval for ...
... science project being conducted jointly by the universities in ... Center. The support is to be provided over a ... project managers, Professor Dr. Angelika Khnle and Dr. Wolfgang ... Gutenberg University Mainz (JGU), were notified of the grant ...
... scientist at Michigan Technological University has discovered a chemical reaction ... it also creates something useful. And, by the way, it ... new, but carbon dioxide molecules are so stable that those ... energy were to come from fossil fuels, over time the ...
Cached Biology Technology:Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors 2Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors 3Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors 4Paratek Announces Appointments of Dennis Molnar as Chief Executive Officer and Director and of Dr. Evan Loh as Chief Medical Officer and Chairman of the Board of Directors 5En route to a quantum computer 2
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... have all but disappearedwere home to dozens of species of ... hundreds of species of flowers, and herds of roaming bison. ... by the University of Colorado Boulder has gotten a peek ... once called the tallgrass prairie home: the diverse assortment of ...
... AMHERST, Mass. Usually indigestion is a bad thing, ... Robert Vass at the University of Massachusetts Amherst recently ... partial degradation of a DNA replication protein is required ... one of the most highly controlled biological processes in ...
... Institute of Biotechnology have used the power of ... atomic movements. The research is helping to chart ... "glycomes" - the entire complement of carbohydrates within ... new understanding of these vital biomolecules which play ...
Cached Biology News:CU-Boulder-led team gets first look at diverse life below rare tallgrass prairies 2Biochemists find incomplete protein digestion is a useful thing for some bacteria 2Gaming technology unravels 1 of the most complex entities in nature 2Gaming technology unravels 1 of the most complex entities in nature 3
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
Clarin Mounting Medium (Permanent environmentally safe mounting medium for general histology & cytology use)...
... formulated for covering tissue sections and cell preparations ... alcohol insoluble end products. UltraMount Plus ... Red or AEC that require an aqueous mounting ... DAB. No heating is required prior to use. ...
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
Biology Products: